Soluble apoptotic factors and adhesion molecules in rhegmatogenous retinal detachment

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4256-4262

  Ricker, Lukas J A G ^a,b   Altara, Raffaele ^b   Goezinne, Fleur ^a   Hendrikse, Fred ^a   Kijlstra, Aize ^a   La Heij, Ellen C ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; FAS ANTIGEN; FAS LIGAND; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; RETINA DETACHMENT; SCLERA BUCKLING PROCEDURE; SUBRETINAL FLUID; VITREORETINOPATHY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RETINA;

ADULT; AGED; APOPTOSIS; CELL ADHESION MOLECULES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; RETINA; RETINAL DETACHMENT; SCLERAL BUCKLING; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80052328271     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6892     Document Type: Article

References (49)

1. Pastor JC, de la Rúa ER, Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144.
2. Pastor JC, Méndez MC, de la Fuente MA, et al. Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. Ophthalmic Res. 2006;38:193-200.
3. Anderson DH, Stern WH, Fisher SK, Erickson PA, Borgula GA. The onset of pigment epithelial proliferation after retinal detachment. Invest Ophthalmol Vis Sci. 1981;21:10-16.
4. Del Priore LV, Hornbeck R, Kaplan HJ, et al. Débridement of the pig retinal pigment epithelium in vivo. Arch Ophthalmol. 1995;113:939-944.
5. Dieudonné SC, La Heij EC, Diederen R, et al. High TGF-β2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2004;45:4113-4118.
6. Chang JH, Kang SW, Ham DI. Sensitivity of CD95-induced apoptosis in different proliferative status of human retinal pigment epithelial cells. Korean J Ophthalmol. 2001;15:74-80.
7. Esser P, Bartz-Schmidt KU, Walter P, Kaszli F, Heimann K, Weller M. Apoptotic cell death in proliferative vitreoretinopathy. German J Ophthalmol. 1996;5:73-78.
8. Weller M, Heimann K, Bartz-Schmidt KU, Fontana A, Esser P. CD95 expression in traumatic proliferative vitreoretinopathy: a target for the induction of apoptosis. German J Ophthalmol. 1997;5:332-337.
9. El Ghrably I, Powe DG, Orr G, et al. Apoptosis in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2004;45:1473-1479.
10. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263: 1759-1762.
11. Janssen O, Qian J, Linkermann A, Kabelitz D. CD95 ligand: death factor and costimulatory molecule? Cell Death Differ. 2003;10: 1215-1225.
12. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med. 2000;191:1209-1219.
13. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045-2050.
14. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31-36.
15. Schneider P, Holler N, Bodmer JL, et al. Conversion of membranebound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205-1213.
16. Sugita S, Taguchi C, Takase H, et al. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis. Br J Ophthalmol. 2000;84:1130-1134.
17. Cardier JE, Schulte T, Kammer H, Kwak J, Cardier M. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells. FASEB J. 1999;13:1950-1960.
18. Barile GR, Chang S, Park L, Reppucci VS, Schiff WM, Schmidt AM. Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Curr Eye Res. 1999;19: 219-227.
19. Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121-125.
20. Ricker LJAG, Kijlstra A, de Jager W, Liem ATA, Hendrikse F, La Heij EC. Chemokine levels in subretinal fluid obtained during scleral buckling surgery after rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci. 2010;51:4143-4150.
21. Ricker LJAG, Dieri RA, Beckers GJ, et al. High subretinal fluid procoagulant activity in rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci. 2010;51:5234-5239.
22. Zhang X, Barile G, Chang S, et al. Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression. Curr Eye Res. 2005;30:395-403.
23. Esser P, Heimann K, Bartz-Schmidt KU, et al. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-β-induced RPE cell apoptosis. Exp Eye Res. 1997;65:365-378.
24. Quintyn JC, Brasseur G. Subretinal fluid in primary rhegmatogenous retinal detachment: physiopathology and composition. Surv Ophthalmol. 2004;49:96-108.
25. Watanabe-Fukunaga R, Brannan C, Itoh N, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol. 1992;148:1274-1279.
26. Liles W, Kiener P, Ledbetter J, Aruffo A, Klebanoff S. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 1996;184:429-440.
27. Richardson B, Lalwani N, Johnson K, Marks R. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol. 1994;24:2640-2645.
28. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630-632.
29. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of the T cell lineage. J Immunol. 1995;154:3806-3813.
30. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
31. Zacks DN, Zheng QD, Han Y, Bakhru R, Miller JW. Fas-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci. 2004;45:4563-4569.
32. McKechnie NM, King BCR, Fletcher E, Braun G. Fas-ligand is stored in secretory lysosomes of ocular barrier epithelia and released with microvesicles. Exp Eye Res. 2006;83:304-314.
33. Jiang S, Wu MWH, Sternberg P, Jones DP. Fas mediates apoptosis and oxidant-induced cell death in cultured hRPE cells. Invest Ophthalmol Vis Sci. 2000;41:645-655.
34. Zacks DN, Boehlke C, Richards AL, Zheng QD. Role of the Fassignaling pathway in photoreceptor neuroprotection. Arch Ophthalmol. 2007;125:1389-1395.
35. Hisatomi T, Sakamoto T, Goto Y, et al. Critical role of photoreceptor apoptosis in functional damage after retinal detachment. Curr Eye Res. 2002;24:161-172.
36. Besirli CG, Chinskey ND, Zheng QD, Zacks DN. Inhibition of retinal detachment-induced apoptosis in photoreceptors by a small peptide inhibitor of the Fas receptor. Invest Ophthalmol Vis Sci. 2010;51:2177-2184.
37. Tarkowski E, Rosengren L, Blomstrand C, Jensen C, Ekholm S, Tarkowski A. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke. 1999;30:321-327.
38. Dupont PJ, Warrens AN. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation. Immunology. 2006;120:133-139.
39. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA. 1997;94:3943-3947.
40. Toyozaki T, Hiroe M, Saito T, et al. Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. Am J Cardiol. 1998;81:798-800.
41. Yasuda N, Gotoh K, Minatoguchi S, et al. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med. 1998;92:993-999.
42. Chen DY, Lan JL, Lin FJ, Hsieh TY. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease. Clin Rheumatol. 2007;26:393-400.
43. El-Agroudy AE, El-Baz A. Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients. Clin Exp Nephrol. 2010;14:152-157.
44. Reinhard T, Bönig H, Mayweg S, Böhringer D, Göbel U, Sundmacher R. Soluble Fas ligand and transforming growth factor β2 in the aqueous humor of patients with endothelial immune reactions after penetrating keratoplasty. Arch Ophthalmol. 2002;120:1630-1635.
45. Limb GA, Franks WA, Munasinghe KR, Chignell AH, Dumonde DC. Proliferative vitreoretinopathy: an examination of the involvement of lymphocytes, adhesion molecules and HLA-DR antigens. Graefes Arch Clin Exp Ophthalmol. 1993;231:331-336.
46. Limb GA, Chignell AH, Cole CJ, et al. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1997;38:1043-1048.
47. Leeuwenberg JFM, Smeets EF, Neefjes JJ, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 1992;77:543-549.
48. Platts KE, Benson MT, Rennie IG, Sharrard RM, Rees RC. Cytokine modulation of adhesion molecule expression on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1995;36:2262-2269.
49. Zacks DN. Gene transcription profile of the detached retina (an AOS thesis). Trans Am Ophthalmol Soc. 2009;107:343-382.